BioCardia, Inc. · NASDAQ:BCDA

BioCardia — Investor Presentation (March 2023)

21 slides from BioCardia's investor presentation, Mar 29, 2023

  1. Slide 1: Corporate Presentation

    Developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases Corporate Presentation BioCardia, Inc. (NASDAQ: BCDA) Peter Altman, PhD President and CEO paltman@biocardia.com www.biocardia.com www.cardiamp.com 05295-W (MKT) Corporate Presentation March 2

  2. Slide 2: Presentation Content and Forward-Looking Statements

    Presentation Content and Forward-Looking Statements Presentation Content No part of this presentation or the information herein may be reproduced, photocopied, redistributed or passed on, directly or indirectly, to any other person, or published, in whole or in part, for any purpose without the cons

  3. Slide 3: Three Platforms, Four Clinical Stage Product Candidates

    Three Platforms, Four Clinical Stage Product Candidates for Cardiovascular and Pulmonary Diseases Product 2023 Platform Candidate Preclinical Phase 1 Phase 2 Phase 3 Anticipated Catalysts Recent Significant Events CardiAMP® for Ischemic Heart Failure (HFrEF) Q2’23: Submission Japan BCDA-01 and DSMB

  4. Slide 4: Selected Financial Data

    Selected Financial Data BioCardia, Inc. (NASDAQ: BCDA) Cash Runway into September 2023 without additional revenue or financing. Year Year Year Ended Ended Ended 31-Dec-22 31-Dec-21 31-Dec-20 ($ mm) ($ mm) ($ mm) Revenues $1.4 $1.0 $0.1 Net Loss $11.9 $12.6 $15.0 Cash used in $10.6 $10.4 $12.4 operat

  5. Slide 5: Problem: Heart failure is an Enormous Unmet Disease

    Problem: Heart failure is an Enormous Unmet Disease • Affects more than 26 million people worldwide, with 50% mortality at five years. • No existing therapies are curative, they currently only slow disease progression. • Recent data shows newer meds only reduce mortality by 0.3%/year (sodium glucose

  6. Slide 6: Current Options for Patients - Expensive, Unable to Heal Failing Hearts

    Current Options for Patients - Expensive, Unable to Heal Failing Hearts Class I, II. & III Class III Class IV Medications Devices Hemodynamic Transplantation (Tx)  Beta-Blockers  CRT & CRT-D Support  Immuno-  Mineralocorticoid  Mitral valve • IV Inotropes suppression receptor antagonists repair

  7. Slide 7: Potential Solution: Cell Based Therapy

    Potential Solution: Cell Based Therapy  Two basic approaches: 1. Deliver cells to repopulate damaged heart tissue with contractile heart cells  Studies repopulating the heart using embryonic or induced pluripotent stem cells are beginning  No safety or efficacy results in humans are available 2.

  8. Slide 8: Potential Solution: ABM MNC Therapy Mechanism of Action

    Potential Solution: ABM MNC Therapy Mechanism of Action  Autologous bone marrow mononuclear cells (ABM MNC) home to heart in injury  In preclinical studies, ABM MNC have: 1. reduced inflammation 2. reduced oxidative stress 3. reduced cell apoptosis 4. increased angiogenesis 5. limited reactive fib

  9. Slide 9: Potential Solution: Cell Based Therapy Role in Continuum of HF Care

    Potential Solution: Cell Based Therapy Role in Continuum of HF Care LVAD/TX PA Pressure Monitoring MV repair CRT Potential of CardiAMP Cell Therapy Modified from Decision Making in Advanced Heart Failure A Scientific Statement From the American Heart Association, Circ 2012 9 05295-W (MKT) Corporate

  10. Slide 10: CardiAMP Cell Therapy is a Significant Advance

    CardiAMP Cell Therapy is a Significant Advance The 1st cardiac cell therapy that combines a pre-procedural assay, point of care cell processing system and transendocardial delivery system. How is it unique from other cardiac cell therapies? 1st test for a cardiac cell therapy that Patient Selection

  11. Slide 11: Autologous Mononuclear Cells: CardiAMP Cell Therapy

    Autologous Mononuclear Cells: CardiAMP Cell Therapy For ischemic HFrEF (BCDA-01) and for Chronic Myocardial Ischemia (BCDA-02) FDA CBER regulated as device system. Medicare reimbursement established for two pivotal trials. 05295-W (MKT) Corporate Presentation March 29, 2023 11

  12. Slide 12: CardiAMP HF: Phase III Pivotal Trial to Support FDA Approval (BCDA-01)

    CardiAMP HF : Phase III Pivotal Trial to Support FDA Approval (BCDA-01) NCT02438306, IDE Trial for Premarket Approval 250 Ischemic Heart Failure Patients at up to 40 centers 20% ≤ Left Ventricular Ejection Fraction ≤ 40% NYHA Class II and III CardiAMP Potency Assay Meets Thresholds 150 Patients @200

  13. Slide 13: 2022 Updates (BCDA-01)

    CardiAMP Cell Therapy Potential Solution in Heart Failure 2022 Updates (BCDA-01) Breakthrough Device Designation granted by FDA based on results from three trials to date: • Improved exercise tolerance/distance • Improved heart function References: • TABMMI Trial, de la Fuente et al, Eurointerventio

  14. Slide 14: 100% Survival, Patient Benefits and Positive Cardiac Remodeling; 2-Year Results

    100% Survival, Patient Benefits and Positive Cardiac Remodeling; 2-Year Results from CardiAMP in HFrEF Phase III Roll In Cohort (BCDA-01) Six Minute Walk Distance Sources of data and additional resources: Cell Potency Assay: Johnston P et al Circ Res, 2018. Phase I: De la Fuente LM, et al. EuroInter

  15. Slide 15: CardiAMP Chronic Myocardial Ischemia Trial (BCDA-02)

    CardiAMP Chronic Myocardial Ischemia Trial (BCDA-02) NCT03455725, IDE Trial for Premarket Approval Burden of Illness and Unmet Need  Characterized by severe chest pain.  Patients suffer from poor perceived health status and psychological distress, have significant impairment in quality of life, an

  16. Slide 16: 2nd Platform: Allogeneic NK1R+ Mesenchymal Stem Cells

    2nd Platform: Allogeneic NK1R+ Mesenchymal Stem Cells Targeting heart failure patients excluded from CardiAMP (BCDA-03) NK1R+ MSC in Heart Failure (BCDA-03)  Treats patients not possible to be treated with CardiAMP ~30% who do not meet cell population analysis in BCDA-01.  “Off the shelf” cell the

  17. Slide 17: Allogenic Neurokinin 1 Receptor Positive MSC in ARDS (BCDA-04)

    Allogenic Neurokinin 1 Receptor Positive MSC in ARDS (BCDA-04) NCT05491681 IND Phase I/II Trial  IND Approved by FDA April 2022 with initial focus on patients recovering from Acute Respiratory Distress (ARDS).  The anti-inflammatory effects of MSC have been well-documented and MSC have been shown

  18. Slide 18: 3rd Platform: Helix Biotherapeutic Delivery System

    3rd Platform: Helix Biotherapeutic Delivery System for Bio-Interventional Cardiology (BCDA 01, 02, 03 and Partners)  Approved in EU, Investigational in USA & Canada  Partnering with other firms for cell, gene, exosome, and protein-based therapies  Published results from clinical studies show enha

  19. Slide 19: Intellectual Property Overview

    Intellectual Property Overview  Exclusive rights to over 60 patents and patent applications in USA, Europe, China, India, and Japan with goal to protect the company’s platform and therapeutic initiatives 05295-W (MKT) Corporate Presentation March 29, 2023 19

  20. Slide 20: Team

    Team Peter Altman, David Ian Sujith Debby Edward Brent PhD McClung McNiece, Shetty, MD Holmes- Gillis Seybold PhD Higgin CEO Chief Chief Chief VP SVP VP Financial Scientific Medical Clinical Devices Development Officer Officer Officer 05295-W (MKT) Corporate Presentation March 29, 2023 20

  21. Slide 21: Three Platforms, Four Clinical Stage Product Candidates

    Three Platforms, Four Clinical Stage Product Candidates for Cardiovascular and Pulmonary Diseases Product 2023 Platform Candidate Preclinical Phase 1 Phase 2 Phase 3 Anticipated Catalysts Recent Significant Events CardiAMP® for Ischemic Heart Failure (HFrEF) Q2’23: Submission Japan BCDA-01 and DSMB

BioCardia — Investor Presentation (March 2023) on 6ix